Navigation Links
MEDIHONEY Used to Prevent Amputation of Patient's Leg
Date:1/13/2009

Clinicians at major NY hospital tout MEDIHONEY(TM) at press conference

PRINCETON, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that MEDIHONEY was the focus of a major press conference last week at North Shore Long Island Jewish Hospital in Manhasset, NY. At the press conference, clinicians detailed the case of a patient who appeared to be heading towards a lower extremity amputation (LEA) due to a non-healing wound associated with an extremely rare fungal infection.

Video clips of the press conference were subsequently aired on several new broadcasts throughout the NY region. To view these clips, please go to the following links:

http://www.newsday.com/news/health/ny-lihone0109,0,7667575.story

http://abclocal.go.com/wabc/story?section=news/health&id=6593764

According to Mary Brennan, RN, CWOCN, Clinical Nurse Specialist for Wounds at North Shore, "MEDIHONEY helped to turn this wound around for him and allowed us back on track for healing. We had used other therapies, but this was the product that made the difference in a very short time."

There are over 50,000 LEAs each year in the United States alone. The 3-year mortality rate post-LEA is estimated to be around 50%.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey- based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from the University of Southern California in Q4 of 2007. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

    Contact: Derma Sciences, Inc.             Allen & Caron Inc
             Edward J. Quilty                 Rudy Barrio (US Investors)
             Chairman and CEO                 r.barrio@allencaron.com
             equilty@dermasciences.com
             (609) 514-4744                   Brian Kennedy (media)
                                              brian@allencaron.com
                                              (212) 691-8087


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Derma Sciences Launches Two New MEDIHONEY(TM) Formulations
2. Derma Sciences Receives FDA Clearance to Sell MEDIHONEY(TM) Over the Counter
3. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming WUWHS Conference
4. Derma Sciences MEDIHONEY(TM) Profiled By ABC News Philadelphia Affiliate
5. Derma Sciences Receives Third FDA Clearance for MEDIHONEY(TM) Wound & Burn Dressings
6. New Study Shows the Use of MEDIHONEY(TM) Wound & Burn Dressing is Associated With Reduction in Wound Size
7. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming SAWC Conference
8. Derma Sciences Announces Several Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming APWCA Conference
9. American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness
10. College of American Pathologists Offers Tips on Simple Diabetes Prevention in the New Year
11. Photos: Arthritis Foundation Launches Nationwide Movement Encouraging People to Move to Prevent and Treat Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... , ... “Journey to the Light: The Quest for Happiness and Love. . ... to finding herself. “Journey to the Light: The Quest for Happiness and Love. ... writer of newsletters, manuals, and articles, who has recently decided to expand her literary ...
(Date:7/23/2017)... (PRWEB) , ... July 23, 2017 , ... A ... in St. Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly ... of the disease offers very few benefits. , In the cases involved with ...
(Date:7/23/2017)... ... 23, 2017 , ... Technology is making it easier for ... tools are helping patients become more actively involved in their care and maintaining ... survey, released today by the American Hospital Association’s (AHA) Health Forum. , According ...
(Date:7/23/2017)... ... July 23, 2017 , ... Viora Ltd., a ... US Patent No. 9,038,640 by the United States Patent and Trademark Office. The ... combination of Switching, Vacuum, and Cooling mechanisms to further increase the efficacy and ...
(Date:7/21/2017)... ... July 21, 2017 , ... "As a doctor of lung medicine ... catheters available on the market," said an inventor from Center Valley, Pa. "My idea ... the patient." , He developed the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT to offer an ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/5/2017)... 5, 2017 Wolfmet 3D  printed tungsten collimator manufactured by ... and manufacturing combine to progress molecular radiotherapy imaging. ... are unable to accurately quantify the radiation absorbed by those ... the success of this radiotherapy treatment has been available — ... ...
Breaking Medicine Technology: